Dynavax begins clinical trial for new shingles vaccine candidate, Z-1018
Dynavax Technologies Corporation, a renowned player in the biopharmaceutical sector, has made headlines with the initiation of a Phase 1/2 clinical trial for its innovative shingles vaccine candidate, Z-1018. This trial marks a significant step in the development of a vaccine aimed at preventing shingles, a painful condition caused by the reactivation of the varicella-zoster […]